A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer

Authors

Victoria Plamadeala, Helomics Corporation
Joseph L. Kelley, Magee-Womens Hospital of UPMC
John K. Chan, Sutter Cancer Research Consortium
Thomas C. Krivak, The Western Pennsylvania HospitalFollow
Michael J. Gabrin, Helomics CorporationFollow
Stacey L. Brower, Helomics CorporationFollow
Matthew A. Powell, Washington University School of Medicine in St. Louis
Thomas J. Rutherford, Yale University
Robert L. Coleman, University of Texas M.D. Anderson Cancer Center

Journal

Gynecologic Oncology

Publication Date

2015

Volume

136

Issue

1

Inclusive Pages

94-98

Document Type

Open Access Publication

DOI

10.1016/j.ygyno.2014.11.019

Rights and Permissions

Victoria Plamadeala, et al. A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer. Gynecologic Oncology, 136(1):94-98. doi:10.1016/j.ygyno.2014.11.019

Recommended Citation

Plamadeala, Victoria; Kelley, Joseph L.; Chan, John K.; Krivak, Thomas C.; Gabrin, Michael J.; Brower, Stacey L.; Powell, Matthew A.; Rutherford, Thomas J.; and Coleman, Robert L., "A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer." Gynecologic Oncology. 136, 1. 94-98. (2015).
https://digitalcommons.wustl.edu/open_access_pubs/3576